" class="no-js "lang="en-US"> Nuevocor - Medtech Alert
Saturday, September 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Nuevocor | Pharmtech Focus

Nuevocor

About Nuevocor

Nuevocor

Nuevocor is a new biotech start-up in Singapore striving to develop gene therapies for genetic cardiomyopathies. It will leverage a deep understanding of cardiac cell biology, as well as a technology platform encompassing novel gene therapy vectors and proteomics-based target discovery

Related Story

Cardiovascular

 Nuevocor Closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies | Pharmtech Focus

Nuevocor Closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies

June 21 2021

Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has announced the completion […]